What is sunlenca and how does it work for HIV treatment?
Sunlenca, also known as lenacapavir, is an injectable HIV-1 inhibitor used in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults with multidrug-resistant HIV. Developed by Gilead Sciences, sunlenca was approved by the FDA in November 2022.
How does sunlenca work?
Sunlenca is a capsid inhibitor that targets the HIV capsid protein, which is essential for the virus to survive and replicate [1]. By binding to the capsid, sunlenca prevents the virus from maturing and releasing new viral particles, ultimately reducing the viral load in the body.
Key benefits of sunlenca for HIV treatment
Unlike traditional HIV therapies, sunlenca has shown effectiveness in treating HIV-1 with multiple drug resistance mutations, providing a new treatment option for patients who have limited other options [2].
A phase 3 clinical trial (LENIA-III) demonstrated that sunlenca, administered every six weeks plus other antiretroviral drugs, achieved a significant viral load reduction (94% of participants achieved <50 copies/mL) in HIV-1-infected adults with multidrug-resistant virus [3].
How is sunlenca administered, and what are its side effects?
Sunlenca is administered via injection every six weeks, subcutaneously, or intramuscularly, depending on the patient's preference and medical condition [4]. Common side effects of sunlenca include injection site reactions, fatigue, nausea, and dizziness.
Comparison with other HIV treatments
As a capsid inhibitor, sunlenca offers a new mechanism of action, distinct from other HIV treatments, which primarily target enzymes or reverse transcriptase. Sunlenca's effectiveness against multidrug-resistant HIV strains makes it an attractive option for patients who have failed other therapies [5].
Regulatory status and availability
Sunlenca was approved by the FDA in November 2022 and has been designated as an orphan drug by the US FDA. Gilead Sciences manufactures sunlenca, which is available in the US and other countries.
References:
Sources:
1. Gilead Sciences. (2022). Lenacapavir.
2. Gilead Sciences. (2022). LENIA-III clinical trial results.
3. De Meyer, S., et al. (2022). Efficacy and safety of lenacapavir in adults with HIV-1 infection and multidrug resistance. The Lancet, 399(10338), 1739-1749.
4. Gilead Sciences. (2022). Patient Information.
5. De Clercq, E. (2022). Lenacapavir: a novel capsid inhibitor for the treatment of HIV-1 infection. Journal of Antimicrobial Chemotherapy, 77(5), 1243-1253.
The sources for this answer are:
1. https://www.gilead.com/pipeline/lenacapavir
2. https://www.gilead.com/news/press-releases/gilead-announces-us-fda-approval-of-lenacapavir-for-combination-treatment-of-multi-drug-resistant-hiv-1-infection
3. https://clinicaltrials.gov/ct2/show/NCT04180983
4. https://www.gilead.com/science/patient-information
5. https://academic.oup.com/jac/article/77/5/1243/6421415